Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
Vaccine
; 42(5): 1051-1064, 2024 Feb 15.
Article
in En
| MEDLINE
| ID: mdl-37816655
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vaccines, Subunit
/
COVID-19
Limits:
Animals
/
Humans
Language:
En
Journal:
Vaccine
Year:
2024
Document type:
Article
Affiliation country:
India